Eagle Pharmaceuticals, inc. (EGRX)

[Bickema]

WIth a market cap of 880 million and cash on hand at 170 million, per last quarter earnings, Eagle has an EV of 710 million. Which I think looks pretty cheap.

Bendeka is now bringing in roughly 40 million in royalty revenue per quarter. However Treanda generics can launch in November of 2019.

So at the very least Eagle has another 8 quarters of 40 million royalty revenue coming there way. So at the very least, that leaves an EV of (710-320) of 390 million for the entire pipeline including Bendeka post 2019. Again this implies 0 dollars for Bendeka post generics which obviously will not happen.

So I personally think 390 million for the entire pipeline and Bendeka post 2019 generics if awfully cheap, however nothing comes easy for Eagle, most of their products require litigation against the novel drug's developer and Ryanodex expansion has been rough.

Eagle and the FDA are not seeing eye to eye on EHS expansion, Ecstasy and Meth trial recruitments are going slower than expected.

Sorry my post is a bit of rambling, I currently do not own any Eagle shares but will look to add when I have dry powder.

They are currently in litigation with Elly Lilly in regards to their pemetrexed generic so follow that case as it very likely will be the next newsworthy event for Eagle.